GlassScriptPhysician profile
David A Knechtel
NPI 1932325750
$2,557.83
in general payments reported to CMS, 2019-2025
30 companies · $563 in 2025
The $563 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $462 · 2022: $512 · 2023: $396 · 2024: $625 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,584.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $522.42 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $307.84 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Insmed, INC. | $184.52 | 2022-2025 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.28 | 2021-2025 | Ofev |
| Genzyme Corporation | $164.51 | 2022-2025 | |
| Mylan Specialty L.P. | $156.01 | 2021-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $137.21 | 2021-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $119.70 | 2022-2025 | Zerbaxa |
| Abbvie INC. | $77.06 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.12 | 2022-2024 | Glassia |
| United Therapeutics Corporation | $65.56 | 2021-2023 | Tyvaso |
| Mallinckrodt Hospital Products INC. | $63.18 | 2021-2022 | |
| Grifols USA, LLC | $59.09 | 2021-2023 | Prolastin-C Liquid |
| Daiichi Sankyo INC. | $50.45 | 2021-2022 | |
| Philips North America LLC | $50.22 | 2022-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $50.22 | 2022-2023 | Hillrom - Vest System Model 105 Home Care |
| Ani Pharmaceuticals, INC. | $48.23 | 2024 | Purified Cortrophin Gel |
| Pfizer INC. | $38.70 | 2023 | |
| Jazz Pharmaceuticals INC. | $34.91 | 2024 | |
| Astellas Pharma US INC | $24.53 | 2024 | Cresemba |
| Gilead Sciences, INC. | $22.10 | 2021 | |
| Genentech USA, INC. | $19.28 | 2023 | Xolair |
| Verona Pharma, INC. | $18.73 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $18.57 | 2025 | Yupelri |
| Inogen, INC. | $16.29 | 2024 | |
| Electromed, INC. | $15.44 | 2023 | Smartvest |
| Amgen INC. | $14.99 | 2025 | Tavneos |
| Paratek Pharmaceuticals, INC. | $14.86 | 2024 | Nuzyra |
| Janssen Pharmaceuticals, INC | $14.31 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Knechtel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.